

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Henlius Biotech, Inc.**

**上海復宏漢霖生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2696)**

**DATE OF BOARD MEETING  
AND  
CHANGE OF ADDRESS OF PRINCIPAL PLACE OF  
BUSINESS IN HONG KONG**

**DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) hereby announces that a meeting of the Board of the Company will be held on Thursday, 18 August 2022 for the purpose of considering and approving the interim results of the Company and its subsidiaries for the six months ended 30 June 2022 and the payment of an interim dividend, if any, and transacting any other business.

**CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The Board also announces that with effect from 15 August 2022, the address of the principal place of business in Hong Kong of the Company will be changed from Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong to 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

On behalf of the Board  
**Shanghai Henlius Biotech, Inc.**  
**Wenjie Zhang**  
*Chairman*

Hong Kong, 8 August 2022

*As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.*